JPMorgan Chase & Co. Buys 75,054 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

JPMorgan Chase & Co. boosted its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 36.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,997 shares of the company's stock after buying an additional 75,054 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.22% of Organogenesis worth $899,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in shares of Organogenesis in the fourth quarter valued at about $38,000. Palumbo Wealth Management LLC acquired a new stake in Organogenesis during the 4th quarter worth $65,000. SG Americas Securities LLC increased its holdings in Organogenesis by 66.4% in the fourth quarter. SG Americas Securities LLC now owns 41,746 shares of the company's stock valued at $134,000 after purchasing an additional 16,660 shares during the last quarter. Cornerstone Investment Partners LLC acquired a new stake in shares of Organogenesis in the 4th quarter valued at approximately $162,000. Finally, Barclays PLC raised its holdings in Organogenesis by 251.7% in the third quarter. Barclays PLC now owns 94,809 shares of the company's stock worth $271,000 after purchasing an additional 67,855 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Morgan Stanley lifted their price objective on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Stock Up 6.5 %

NASDAQ:ORGO traded up $0.32 during trading hours on Friday, reaching $5.28. 2,769,835 shares of the stock were exchanged, compared to its average volume of 1,139,545. The stock has a market cap of $669.79 million, a PE ratio of -88.00 and a beta of 1.85. Organogenesis Holdings Inc. has a twelve month low of $2.21 and a twelve month high of $6.71. The firm has a 50 day moving average of $4.63 and a 200 day moving average of $3.84. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Insider Buying and Selling

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares of the company's stock, valued at approximately $851,082.90. This represents a 13.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 36.90% of the stock is currently owned by corporate insiders.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.